Thomas Rooney
Sanofi R&D
Chilly, France
Chilly, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Journal: Bioorganic & medicinal chemistry letters
Published: October 23, 2018
SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: October 26, 2017
NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration.
Journal: Neurobiology of disease
Published: December 13, 2016
In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy.
Journal: Frontiers in aging neuroscience
Published: January 05, 2016
High-throughput 3D whole-brain quantitative histopathology in rodents.
Journal: Scientific reports
Published: January 27, 2015
A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).
Journal: PloS one
Published: November 03, 2014
PKR downregulation prevents neurodegeneration and β-amyloid production in a thiamine-deficient model.
Journal: Cell death & disease
Published: August 25, 2014
Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor.
Journal: Bioorganic & medicinal chemistry letters
Published: September 20, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026